Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
Johan Vansteenkiste(KU Leuven), Byoung Chul Cho(Yonsei University), Tõnu Vanakesa(North Estonia Medical Centre), Tommaso De Pas, M. Zieliński, Moon Soo Kim(National Cancer Center), Jacek Jassem(Gdańsk Medical University), Masahiro Yoshimura(Hyogo Prefectural Cancer Center), Jubrail Dahabreh(Athens Medical Center), Haruhiku Nakayama(Kanagawa Prefectural Hospital Organization), Libor Havel, Haruhiko Kondo(Shizuoka Cancer Center), Tetsuya Mitsudomi(Aichi Cancer Center), Paul Zarogoulidis(G. Papanikolaou General Hospital), Oleg Gladkov(Chelyabinsk Regional Clinical Oncology Center), Katalin Udud(Országos Korányi Tbc és Pulmonológiai Intézet), Hirohito Tada(Osaka City General Hospital), Hans Hoffman, Anders Bugge(Oslo University Hospital), Paul Taylor, Emilio Esteban Gonzalez(Hospital Universitario Central de Asturias), Mei Lin Liao(Shanghai Chest Hospital), Jianxing He(First Affiliated Hospital of Guangzhou Medical University), Jean-Louis Pujol(Hôpital Arnaud de Villeneuve), Jamila Louahed(GlaxoSmithKline (Belgium)), Muriel Debois(GlaxoSmithKline (Belgium)), Vincent Brichard(GlaxoSmithKline (Belgium)), C. Debruyne(GlaxoSmithKline (Belgium)), Patrick Therasse(GlaxoSmithKline (Belgium)), Nasser K. Altorki(Cornell University)
Cited by 496Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis